Chugai Pharmaceutical : Script (including Q&A)

CHUGAI PHARMACEUTICAL CO., LTD.

ESG Meeting

November 16, 2021

Event Summary

[Company Name]	CHUGAI PHARMACEUTICAL CO., LTD.
[Company ID]	4519-QCODE
[Event Language]	JPN
[Event Type]	Analyst Meeting
[Event Name]	ESG Meeting
[Fiscal Period]
[Date]	November 16, 2021
[Number of Pages]	47
[Time]	10:00 - 11:32
	(Total: 92 minutes, Presentation: 62 minutes, Q&A: 30 minutes)
[Venue]	Dial-in
[Venue Size]
[Participants]
[Number of Speakers]	5
	Motoo Ueno	Representative Director, Deputy Chairman
	Toshiaki Itagaki	Executive Vice President & CFO
	Tsukasa Kusano	Vice President, Head of Clinical Development
		Division
	Shigehiro Yamada	Head of Sustainability Department
	Seiji Saito	Digital Engineering Department
	Toshiya Sasai	Head of Corporate Communications
		Department
[Analyst Names]*	Hidemaru Yamaguchi	Citigroup Global Markets Japan Inc.
	Kazuaki Hashiguchi	Daiwa Securities Co. Ltd.
	Shinichiro Muraoka	Morgan Stanley MUFG Securities Co., Ltd.

*Analysts that SCRIPTS Asia was able to identify from the audio who spoke during Q&A.

Support
Japan	03.4405.3160	North America	1.800.674.8375
Tollfree	0120.966.744	Email Support	[e-mail]

1

Presentation

Sasai: Let's get started. Ladies and gentlemen, thank you very much for taking time out of your busy schedules to participate in today's CHUGAI PHARMACEUTICAL ESG briefing. My name is Sasai from Corporate Communications, and I will be moderating today's session. Thank you.

In order to prevent the spread of the coronavirus infection, today's session will be conducted by both on-site presentation and conference call.

The agenda for today's briefing is shown on the screen in the hall, on the web screen, and on the second page of the presentation materials. Our presentation will be in line with the materials. Questions will be taken after all presentations have been completed. The Q&A is scheduled to take about 30 minutes.

Mr. Ueno, Chugai's Representative Director and Deputy Chairman, will now talk about sustainability and management. Thank you.

Ueno: Good morning, everyone. I'm Ueno. Thank you very much for attending the third Chugai ESG briefing.

The social and economic environment is changing rapidly. The coronavirus pandemic has contributed to this. We are facing a variety of societal issues, and we believe that dialogue with our stakeholders is essential in addressing these issues. Today's session will take just under an hour. Today, 110 people are joining us for this event. Of those, less than 10 people are in attendance at the venue. Last year, about 80 people attended the briefing, of whom 20 came to the venue. With the impact of COVID-19, I believe that this is part of the so- called New Normal, where digitalization creates new opportunities for meeting peoples' diverse needs.

Our contact with medical institutions continues to be strained by COVID-19. In this context, we have been holding webinars, which have been well received by doctors who are usually unable to participate due to long distances to travel. I think that hybrid events will continue to take hold in the future.

Support
Japan	03.4405.3160	North America	1.800.674.8375
Tollfree	0120.966.744	Email Support	[e-mail]

2

First of all, I would like to talk about the subject of today's briefing. As I just mentioned, this is our third talk on this topic. In the first presentation, I gave an overview of Chugai's ESG initiatives. In the second presentation, last year, I gave an overview of our main themes.

According to the questionnaire we distributed, some investors said that they had a relatively good understanding of Chugai's individual ESG activities, but they wanted an explanation of how ESG relates to drug discovery and growth strategies. So this time, I'd like to go one step further and focus on how Chugai is promoting ESG as a management strategy, what we are doing, and what we want to do.

I would also like to mention that our management strategy and ESG activities are interdependent.

Going forward, we will continue to hold ESG briefings as well as review our ESG initiatives. We will do this through the PDCA cycle and through dialogue with stakeholders.

Support
Japan	03.4405.3160	North America	1.800.674.8375
Tollfree	0120.966.744	Email Support	[e-mail]

3

Before I make a start on the main topic, I have a message from one of our outside directors.

This is Mr. Ichimaru. As you can see, at Board meetings and presentations, Mr. Ichimaru has given us his frank opinions and advice on ESG initiatives and dialogue with stakeholders.

With the support of outside directors, we would like to continue to make a commitment to ESG.

As mentioned in the second paragraph, in order to realize the " advanced and sustainable patient-centric healthcare " that Chugai advocates, it is necessary and important for each and every employee to consider business activities, including ESG, as a part of their own work, creating shared values in each workplace. It is necessary and important to have continuous dialogue on ESG to understand the expectations and requests from outside. These must be reflected in management, with this process running as a cycle.

Support
Japan	03.4405.3160	North America	1.800.674.8375
Tollfree	0120.966.744	Email Support	[e-mail]

4